Tislelizumab,Platinum
PreclinicalSmall molecule
Tislelizumab,Platinum is one of 36 small molecule programs targeting Lung Adenocarcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Lung Adenocarcinoma
#DrugCompanyPhaseTrials
1Alimta
SShawn Eagle
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Tarceva
OOSI Pharmaceuticals
Approved
Tecentriq
RocheApproved
Taxol
TevaApproved
Abraxane
Bristol-Myers SquibbApproved
Paraplatin
AAvyxa
Approved
Iclusig
TakedaApproved
Lenvima
EisaiApproved
Ensacove
XXcovery Holdings, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tislelizumab,Platinum. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details